Vibrocil drops nasal

Country: Armenja

Lingwa: Ingliż

Sors: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Ingredjent attiv:

dimethindene (dimethindene maleate), phenylephrine

Disponibbli minn:

GlaxoSmithKline Consumer Healthcare S.A.

Kodiċi ATC:

R01BA53

INN (Isem Internazzjonali):

dimethindene (dimethindene maleate), phenylephrine

Dożaġġ:

0,25mg/ml+ 2,5mg/ml

Għamla farmaċewtika:

drops nasal

Unitajiet fil-pakkett:

15ml glass vial

Tip ta 'preskrizzjoni:

OTC

L-istatus ta 'awtorizzazzjoni:

Registered

Data ta 'l-awtorizzazzjoni:

2019-11-27

Karatteristiċi tal-prodott

GSK Consumer Healthcare S.A.
CH-1260 Nyon, Switzerland
Regulatory Affairs
Vibrocil Nasal Drops
Dimetindene maleate 0.025% + Phenylephrine base 0.25%
SUMMARY OF PRODUCT CHARACTERISTICS
Release date:
06 August 2019
Number of pages:
8
Property of GSK Consumer Healthcare S.A.
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK Consumer Healthcare S.A.
GSK Consumer Healthcare S.A.
CONFIDENTIAL
Page 2
Summary of Product Characteristics
Vibrocil
1.
NAME OF THE MEDICINAL PRODUCT
.................................................................. 3
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
........................................ 3
3.
PHARMACEUTICAL FORM
.......................................................................................
3
4.
CLINICAL PARTICULARS
.........................................................................................
3
4.1.
Therapeutic indications
.......................................................................................
3
4.2.
Posology and method of administration
............................................................. 3
4.3.
Contra-indications...............................................................................................
3
4.4.
Special warnings and precautions for use
........................................................... 4
4.5.
Interactions with other medicinal products and other forms of
interaction ........ 4
4.6.
Pregnancy and lactation
......................................................................................
4
4.7.
Effects on ability to drive and use machines
...................................................... 4
4.8.
Undesirable effects
.............................................................................................
4
4.9.
Overdose
.............................................................................................................
5
5.
PHARMACOLOGICAL PROPERTIES
.......................................................................
5
5.1.
Pharmacodynam